For immediate release: June 10, 2014
Contact: Britten Pund, 202-434-8044, bpund@NASTAD.org
Washington, DC – Today, the National Alliance of State & Territorial AIDS Directors (NASTAD) released the 2014 Online AIDS Drug Assistance Program (ADAP) Formulary Database (the Database) and accompanying User’s Guide. The Database details ADAP coverage of medications both individually and by drug class, marking the first time state-by-state ADAP formulary coverage data has been made publicly available in an online searchable format. NASTAD receives frequent requests regarding individual states’ formulary composition. This newly-released online format provides a method to query this data. Medications included in the Database include antiretroviral (ARV) treatments and “A1” Opportunistic Infections (A1 OI) medications, as well as treatments for hepatitis B and C, substance use treatment medications and various vaccines and laboratory tests. The Database includes formulary information from all 50 states as well as the District of Columbia, Guam and Puerto Rico, as of March 31, 2014. Moving forward, the Database will be updated as new information becomes available. In addition, interested parties are encouraged to contact individual ADAPs with specific questions about medication availability. Continue reading
By Chris Taylor, Director, Viral Hepatitis, NASTAD
NASTAD Staff: Left to Right: Murray Penner, Deputy Director; Julie Scofield, Executive Director; Chris Taylor, Director, Viral Hepatitis
Last month, Julie Scofield, Executive Director of the National Alliance of State and Territorial AIDS Directors (NASTAD), was recognized by the White House Office of Drug Control Policy (ONDCP) and Office of National AIDS Policy (ONAP) for her leadership in the prevention and treatment of viral hepatitis. The event was held at the White House in observance World Hepatitis Day. NASTAD congratulates Julie Scofield and other colleagues recognized for their leadership to address the domestic and global viral hepatitis epidemics.
By Tibebe Shenie, Country Director, NASTAD Ethiopia and Anne Sites, Senior Manager, Global Program, NASTAD
Wubshet Denboba, Health System Strengthening Senior Specialist, NASTAD Ethiopia
The recently released UNAIDS Gap Report highlighted many significant achievements in the global fight against HIV/AIDS, including a 13% decrease in new HIV infections and a 19% reduction in AIDS-related deaths over the past three years. But the report also emphasized that much work remains to be done to ‘close the gap’ between those who have access to life-saving services and those who do not. It is critical that Ministries of Health be able to utilize high quality HIV data to address these gaps, and to direct client-level interventions to locations and populations with the greatest need. In Ethiopia, NASTAD is contributing to this effort as it supports the Federal HIV/AIDS Prevention and Control Office (FHAPCO) in the implementation of a Multi-Sectoral Response Information System (MRIS).
By Emily McCloskey, Manager, Policy and Legislative Affairs
http://www.nikeairmaxfreerun.com nike air max 2014
Today, NASTAD released an infographic analyzing viral hepatitis funding. State health departments receive less than $1 dollar in federal funding for every person living with viral hepatitis for the Viral Hepatitis Prevention Coordinator (VHPC) program. The VHPC program is the only national program dedicated to the viral hepatitis epidemics and provides the only public health infrastructure for the prevention of viral hepatitis and linking individuals to care and treatment. In order to meet the goals established by the Viral Hepatitis Action Plan, the VHPC program must continue to be funded in all existing jurisdictions and increased resources are necessary to coordinate prevention efforts at the state and local levels. Continue reading
By Christopher Cannon, Manager, Health Care Access, NASTAD
http://www.nikeairmaxfreedom.com air max
Prior to the approval of Truvada as PrEP, health departments feared there would be a rush of affluent gay men demanding access to Pre-Exposure Prophylaxis (PrEP)-the use of antiretroviral medication to prevent the infection of HIV-to abandon condom use altogether. In so doing, they would create greater health disparities among vulnerable populations like young gay and bisexual men, Black and Latino gay and bisexual men, and transgender women who are often disenfranchised. However interest in PrEP outside of clinical trials across the country has been very limited. Gilead, manufacturer of Truvada, reports only 2,319 prescriptions filled for Truvada as PrEP from January 1, 2012 (prior to FDA approval in July 2012) to September 30, 2013 in the United States, which currently has an estimated 50,000 HIV infections each year. Continue reading